Eby Pharma specializes in the development of a unique gallium nitrate product aimed at treating navicular syndrome and related disorders in horses. The active ingredient, a higher pH, non-citrated form of gallium nitrate, is designed to inhibit bone resorption and stimulate bone formation, providing significant benefits for equine bone health. Research trials have demonstrated that this product can reduce both the incidence and severity of lameness associated with navicular syndrome, often within a two-week period. The formulation is available in two concentrations, 14% and 42%, and is intended for dilution before use, ensuring that horses receive the appropriate dosage for effective treatment.

In addition to its bone health benefits, gallium nitrate also exhibits strong anti-inflammatory and pain-relief properties, making it a comprehensive solution for managing navicular disorders. Eby Pharma emphasizes that their product offers a combination of benefits not found in other treatments, such as Tildren, which only addresses one aspect of the condition. The company provides detailed instructions for use and dosage, ensuring that horse owners can effectively administer the treatment while adhering to safety guidelines. Overall, Eby Pharma's innovative approach to equine health through gallium nitrate represents a significant advancement in the management of navicular syndrome.

United States

Eby Pharma offers a gallium nitrate product to reduce both the incidence of lameness and the severity of navicular syndrome and navicular disorders in horses.

Eby Pharma

Company Details